These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 25180623)

  • 41. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
    Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
    Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Analysis of direct medical and nonmedical costs for care of rheumatoid arthritis patients using the large cohort database, IORRA.
    Tanaka E; Hoshi D; Igarashi A; Inoue E; Shidara K; Sugimoto N; Sato E; Seto Y; Nakajima A; Momohara S; Taniguchi A; Tsutani K; Yamanaka H
    Mod Rheumatol; 2013 Jul; 23(4):742-51. PubMed ID: 22878927
    [TBL] [Abstract][Full Text] [Related]  

  • 44. What are the costs to society and the potential benefits from the effective management of early rheumatoid arthritis?
    March L; Lapsley H
    Best Pract Res Clin Rheumatol; 2001 Mar; 15(1):171-85. PubMed ID: 11358421
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
    Zhou ZY; Griffith J; Du EX; Chin D; Betts KA; Ganguli A
    Adv Ther; 2016 May; 33(5):807-23. PubMed ID: 27084724
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Costs of rheumatoid arthritis in France: a multicenter study of 1109 patients managed by hospital-based rheumatologists.
    Guillemin F; Durieux S; Daurès JP; Lafuma A; Saraux A; Sibilia J; Bourgeois P; Sany J
    J Rheumatol; 2004 Jul; 31(7):1297-304. PubMed ID: 15229947
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Medical and economic aspects of rheumatoid arthritis].
    Fautrel B; Gaujoux-Viala C
    Bull Acad Natl Med; 2012 Oct; 196(7):1295-305; discussion 1305-6. PubMed ID: 23815015
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of remission definition on healthcare cost savings estimates for patients with rheumatoid arthritis treated with biologic therapies.
    Barnabe C; Thanh NX; Ohinmaa A; Homik J; Barr SG; Martin L; Maksymowych WP
    J Rheumatol; 2014 Aug; 41(8):1600-6. PubMed ID: 25028381
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevalence of comorbidities and their associations with health-related quality of life and healthcare expenditures in patients with rheumatoid arthritis.
    An J; Nyarko E; Hamad MA
    Clin Rheumatol; 2019 Oct; 38(10):2717-2726. PubMed ID: 31134504
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The economics of treatment in early rheumatoid arthritis.
    Bansback N; Marra CA; Finckh A; Anis A
    Best Pract Res Clin Rheumatol; 2009 Feb; 23(1):83-92. PubMed ID: 19233048
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Indirect cost assessment in patients with rheumatoid arthritis (RA): comparison of data from the health economic patient questionnaire HEQ-RA and insurance claims data.
    Merkesdal S; Ruof J; Huelsemann JL; Mittendorf T; Handelmann S; Mau W; Zeidler H
    Arthritis Rheum; 2005 Apr; 53(2):234-40. PubMed ID: 15818718
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Medical resource use and costs among rheumatoid arthritis patients receiving disease-modifying antirheumatic drug therapy.
    Griffiths RI; Bar-Din M; MacLean CH; Sullivan EM; Herbert RJ; Yelin EH
    Arthritis Care Res; 2000 Aug; 13(4):213-26. PubMed ID: 14635276
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
    Clark W; Jobanputra P; Barton P; Burls A
    Health Technol Assess; 2004 May; 8(18):iii-iv, ix-x, 1-105. PubMed ID: 15130461
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Value of Remission in Patients with Rheumatoid Arthritis: A Targeted Review.
    Ostor AJ; Sawant R; Qi CZ; Wu A; Nagy O; Betts KA
    Adv Ther; 2022 Jan; 39(1):75-93. PubMed ID: 34787822
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
    Brennan A; Bansback N; Nixon R; Madan J; Harrison M; Watson K; Symmons D
    Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The burden of illness of rheumatoid arthritis.
    Boonen A; Severens JL
    Clin Rheumatol; 2011 Mar; 30 Suppl 1():S3-8. PubMed ID: 21359507
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quantifying the economic burden of productivity loss in rheumatoid arthritis.
    Filipovic I; Walker D; Forster F; Curry AS
    Rheumatology (Oxford); 2011 Jun; 50(6):1083-90. PubMed ID: 21245074
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged > or =65 years with rheumatoid arthritis.
    Weycker D; Yu EB; Woolley JM; Oster G
    Clin Ther; 2005 May; 27(5):646-56. PubMed ID: 15978314
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Optimization of biological therapy in rheumatoid arthritis patients: outcomes from the CREATE registry after 2 years of follow-up.
    Cárdenas MJ; de la Fuente S; Castro-Villegas MC; Romero-Gómez M; Ruiz-Vílchez D; Calvo-Gutiérrez J; Escudero-Contreras A; Del Prado JR; Collantes-Estévez E; Font P
    Rheumatol Int; 2017 Oct; 37(10):1701-1708. PubMed ID: 28597307
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Economics of stratified medicine in rheumatoid arthritis.
    Gavan S; Harrison M; Iglesias C; Barton A; Manca A; Payne K
    Curr Rheumatol Rep; 2014 Dec; 16(12):468. PubMed ID: 25366935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.